By admin 
The escalating crisis within the American Diabetes Association (ADA) reached a fever pitch this week as a coalition of more than 200 prominent members, including some of the world’s leading endocrinologists and researchers, issued a formal demand for the immediate resignation of the organization’s top two executives. The call for the removal of Chief Executive Officer Charles Henderson and Chief Scientific and Medical Officer Dr. Rita Kalyani follows a series of controversial events that began during the ADA’s 2026 Scientific Sessions in New Orleans, an incident that many in the medical community view as a watershed moment for the integrity of the institution. The friction, which has been simmering for over six weeks, centers on the abrupt and forceful expulsion of five respected diabetes experts from the annual meeting, an act that critics describe as a heavy-handed attempt to stifle scientific dissent and protect corporate interests.
In an open letter addressed to the ADA Board of Directors, the signatories expressed profound disillusionment with the current direction of the association, which was founded nearly a century ago to serve as a beacon of objective science and patient advocacy. The letter characterizes the leadership of Henderson and Kalyani as "unsustainable" and "out of touch" with the core mission of the scientific community. Beyond the resignations, the group is demanding a comprehensive, independent investigation into the New Orleans incident, a public and unreserved apology to the five colleagues who were removed, and a formal commitment to restoring the editorial independence of Diabetes Care, the ADA’s flagship peer-reviewed journal. The letter notes with mounting frustration that despite 45 days passing since the New Orleans sessions, the board has failed to take meaningful disciplinary action or offer a transparent account of why the experts were targeted for removal.
The roots of the current rebellion can be traced back to the final days of the Scientific Sessions in New Orleans, an event traditionally reserved for the exchange of cutting-edge research and clinical breakthroughs. While the ADA has not officially detailed the specific reasons for the expulsion of the five experts, sources close to the situation suggest the conflict arose during a high-stakes symposium regarding the socio-economic impacts of next-generation obesity and diabetes medications. The experts in question—recognized for their work on drug pricing transparency and healthcare equity—reportedly challenged the prevailing narrative regarding the accessibility of GLP-1 receptor agonists and dual GIP/GLP-1 agonists. Witnesses describe a scene where security personnel escorted the scientists from the venue after they attempted to present data that contradicted certain industry-sponsored findings presented earlier in the week.
This incident has reignited a long-standing debate over the influence of the pharmaceutical industry on the ADA’s clinical guidelines and public policy stances. The ADA, like many large medical nonprofits, relies heavily on corporate sponsorships and industry grants to fund its massive annual meetings and research initiatives. However, the expulsion of scientists during a live session is seen by many as a bridge too far, signaling a shift from collaborative partnership to what some call "administrative censorship." The open letter emphasizes that the ADA’s strength must flow from the community of physicians and scientists it serves, rather than from the professional administrators who manage its day-to-day operations.
Dr. Kalyani, who has served as the Chief Scientific and Medical Officer, has been a particular focus of the members’ ire. Critics argue that under her tenure, the boundary between the association’s scientific output and its administrative goals has become dangerously blurred. The demand for "editorial independence" at Diabetes Care suggests that there are internal concerns regarding the vetting process for published research, with some members alleging that studies critical of high drug prices or those favoring generic alternatives face more rigorous—and perhaps biased—gatekeeping than those supported by major manufacturers. The integrity of Diabetes Care is paramount; as one of the most cited journals in the field of endocrinology, its publications dictate the standards of care for millions of patients worldwide. Any perception of corporate meddling could have catastrophic effects on clinical trust.
In a brief and carefully worded response issued on Tuesday, the ADA board attempted to de-escalate the situation without making any immediate concessions. The statement expressed a generic appreciation for the "patience" of the membership while an internal report is being prepared. However, this response has done little to quell the uprising. For the signatories of the open letter, the promise of an internal report is seen as a stalling tactic designed to let the controversy fade from the news cycle. "A report prepared by the very organization under scrutiny is not a substitute for accountability," the letter states, reinforcing the need for an external, third-party probe.
The controversy comes at a precarious time for the diabetes community. With the global prevalence of diabetes continuing to climb and the introduction of transformative but prohibitively expensive new therapies, the role of the ADA as an objective arbiter has never been more critical. If the organization is perceived as being "captured" by administrative or corporate interests, its ability to influence legislation, such as the push for insulin price caps or expanded coverage for weight-loss medications, could be severely compromised. Lawmakers and public health officials rely on the ADA’s "Standards of Care" as the gold standard for policy-making. If the scientific community loses faith in those standards, the entire infrastructure of diabetes advocacy in the United States could begin to fracture.
Furthermore, the demographic of the signatories suggests that this is not a localized or fringe movement. The list includes former ADA presidents, department chairs from top-tier medical schools, and internationally recognized clinical trialists. Their collective stance represents a significant portion of the ADA’s intellectual capital. The "2026" incident in New Orleans appears to have been the final straw for a membership that has grown increasingly weary of what they describe as the "corporatization" of the ADA. They argue that the CEO, Charles Henderson, whose background is in nonprofit management rather than clinical medicine, has prioritized brand expansion and revenue streams over the rigorous, sometimes uncomfortable, scientific debates that are necessary for medical progress.
The demand for an apology to the five expelled experts is not merely a matter of professional courtesy; it is a demand for the re-establishment of the "safe harbor" principle in scientific discourse. In academic circles, the ability to challenge data and present dissenting views without fear of professional retaliation is considered a foundational right. By using security to remove dissenters, the ADA leadership is accused of creating a "chilling effect" that could discourage younger researchers from pursuing lines of inquiry that might be unpopular with the organization’s leadership or its donors.
As the standoff continues, the ADA Board of Directors finds itself in a difficult position. To fire Henderson and Kalyani would be a massive admission of failure and could disrupt the organization’s operational stability. However, to ignore the demands of over 200 of its most influential members risks a mass exodus of talent and a permanent stain on the association’s reputation. There are already reports of members discussing the formation of a new, alternative professional body that would prioritize academic freedom and transparency in its bylaws.
The coming weeks will likely determine the future of the American Diabetes Association for the next decade. If the board chooses to double down on its current leadership, it may find itself presiding over a hollowed-out institution, stripped of the scientific authority that once made it the premier voice in the field. If it moves toward the requested reforms—including the resignations and the independent investigation—it faces a painful period of restructuring but may ultimately emerge with its credibility intact. For the millions of people living with diabetes, the stakes could not be higher. They depend on an ADA that puts patients and science above administrative convenience and corporate harmony. As the open letter poignantly concludes, the current path is "unsustainable," and the time for a fundamental change in the organization’s DNA has arrived. The world is watching to see if the ADA can return to its roots or if the New Orleans sessions will be remembered as the beginning of the end for a storied institution.
